Horizontal Aorta in Transcatheter Self-Expanding Valves: Insights From the HORSE International Multicentre Registry

Gallo, Francesco; Gallone, Guglielmo; Kim, Won Keun; Reifart, Jörg; Veulemans, Verena; Zeus, Tobias; Toggweiler, Stefan; Søndergaard, Lars; Mangieri, Antonio; Khokhar, Arif; Marco, Federico De; Regazzoli, Damiano; Reimers, Bernhard; Muntané‐Carol, Guillem; Estévez‐Loureiro, Rodrigo; Espino, Antonio; Moscarelli, Marco; Mylotte, Darren; Bhadra, Oliver D.; Conradi, Lenard; Donday, Luis Alfonso Marroquin; Nombela‐Franco, Luis; Barbanti, Marco; Reddavid, Claudia; Criscione, Enrico; Brugaletta, Salvatore; Regueiro, Ander; Pérez-Fuentes, Pedro; Nicolini, Elisa; Piva, Tommaso; Tzanis, Giorgos; Rodés‐Cabau, Josep; Colombo, Antonio; Giannini, Francesco

doi:10.1161/circinterventions.121.010641

Cited by 19 publications

(11 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Similarly, the HORSE registry showed that TAVI in patients with an AA more than 49 • was associated with worst outcomes. However, among these cases, patients treated with ACURATE Neo valve showed more favourable outcomes in comparison with these cases treated with the EVOLUTE R/PRO THV [46].…”

Section: Patients With Horizontal Aortamentioning

confidence: 85%

Personalised Treatment in Aortic Stenosis: A Patient-Tailored Transcatheter Aortic Valve Implantation Approach

Mitsis

Yuan

Eftychiou

et al. 2022

JCDD

View full text Add to dashboard Cite

Transcatheter aortic valve replacement (TAVI) has become a game changer in the management of severe aortic stenosis shifting the concept from inoperable or high-risk patients to intermediate or low surgical-risk individuals. Among devices available nowadays, there is no clear evidence that one device is better than the other or that one device is suitable for all patients. The selection of the optimal TAVI valve for every patient represents a challenging process for clinicians, given a large number of currently available devices. Consequently, understanding the advantages and disadvantages of each valve and personalising the valve selection based on patient-specific clinical and anatomical characteristics is paramount. This review article aims to both analyse the available devices in the presence of specific clinical and anatomic features and offer guidance to select the most suitable valve for a given patient.

show abstract

Section: Patients With Horizontal Aortamentioning

confidence: 85%

Personalised Treatment in Aortic Stenosis: A Patient-Tailored Transcatheter Aortic Valve Implantation Approach

Mitsis

Yuan

Eftychiou

et al. 2022

JCDD

View full text Add to dashboard Cite

show abstract

“…The HORSE registry is an international registry in which patients undergoing transfemoral TAVI using self-expandable valves were retrospectively enrolled across sixteen European centers between September 2014 and April 2020 [10]. All patients provided informed consent to participate in the registry and agreed to the use of their data for scientific purposes.…”

Section: Methodsmentioning

confidence: 99%

Comparison of Mid-Term Prognosis in Intermediate-to-Low-Risk Contemporary Population with Guidelines-Oriented Age Cutoff

Benenati,

Gallo,

Kim

et al. 2024

JCDD

Self Cite

View full text Add to dashboard Cite

Background: Current European guidelines support transcatheter aortic valve implantation (TAVI) in intermediate-to-low-risk patients ≥75 years-old, but its prognostic relevance is unknown. Methods: Intermediate-to-low-risk (The Society of Thoracic Surgeons score <8%) patients enrolled in the HORSE registry were included. We compared the populations aged under 75 with those over 75. The primary endpoint was all-cause mortality. Results: A total of 2685 patients were included: 280 (8.6%) < 75 and 2405 ≥ 75 years. Through a mean follow-up of 437 ± 381 days, 198 (8.2%) and 23 (8.2%) patients died in the two arms without statistically significant differences (log-rank p = 0.925). At Cox regression analysis, age did not predict the occurrence of all-cause death, neither as a continuous variable (HR 1.01, 95% CI 0.99–1.04, p = 0.294) nor dichotomizing according to the prespecified cutoff of 75 years (HR 0.97, 95% CI 0.63–1.51, p = 0.924). Time-to-event ROC curves showed low accuracy of age to predict all-cause mortality (area under the curve of 0.54 for both 1-year and 2-year outcomes). Conclusions: TAVI has comparable benefits across age strata for intermediate-to-low-risk patients. The age cutoff suggested by the current guidelines is not predictive of the risk of adverse events during hospital stays or of all-cause mortality through a mid-term follow-up.

show abstract

“…The HORSE registry is an international registry in which patients undergoing transfemoral TAVI using self-expandable valves were retrospectively enrolled across sixteen European centers between September 2014 and April 2020 [10]. All patients provided informed consent to participate in the registry and agreed with the use of their data for scientific purposes.…”

Section: Methodsmentioning

confidence: 99%

Prognostic Impact of Guidelines-oriented Age Cut-off in Intermediate-to-low Risk Patients Undergoing Transcatheter Aortic Valve Implantation in a Large Real-world Multicenter Registry

Benenati¹,

Gallo²,

Kim³

et al. 2023

Preprint

View full text Add to dashboard Cite

Background: Current European guidelines support transcatheter aortic valve implantation (TA-VI) in intermediate to low-risk patients ≥75 years-old but its prognostic relevance is unknown. Methods: Intermediate-to-low-risk (Society of Thoracic Surgeon score <8%) patients enrolled in the HORSE registry were included. We compared the population with less versus more than 75 years old. The primary endpoint was all-cause mortality. Results: A total of 2685 patients were included, 280 (8.6%) <75 and 2405 ≥75 years. Through a mean follow-up of 437 ± 381 days, 198 (8.2%) and 23 (8.2%) patients died in the two arms, without statistically significant differences (log-rank p=0.925). At Cox regression analysis, age did not predict the occurrence of all-cause death, neither as a continuous variable (HR 1.01, 95% CI 0.99-1.04, p=0.294) nor dichotomizing according to the prespecified cutoff of 75 years (HR 0.97, 95% CI 0.63-1.51p=0.924). Time-to-event ROC curves showed low accuracy of age to predict all-cause mortality (area under the curve of 0.54 for both 1-year and 2-year outcomes). Conclusions: TAVI has comparable benefits across age strata in intermediate-to-low risk patients. The age cut-off suggested by current guidelines is not predictive of the risk of adverse events during hospital stay, neither of all-cause mortality through a mid-term follow-up.

show abstract

Horizontal Aorta in Transcatheter Self-Expanding Valves: Insights From the HORSE International Multicentre Registry

Cited by 19 publications

References 28 publications

Personalised Treatment in Aortic Stenosis: A Patient-Tailored Transcatheter Aortic Valve Implantation Approach

Personalised Treatment in Aortic Stenosis: A Patient-Tailored Transcatheter Aortic Valve Implantation Approach

Comparison of Mid-Term Prognosis in Intermediate-to-Low-Risk Contemporary Population with Guidelines-Oriented Age Cutoff

Prognostic Impact of Guidelines-oriented Age Cut-off in Intermediate-to-low Risk Patients Undergoing Transcatheter Aortic Valve Implantation in a Large Real-world Multicenter Registry

Contact Info

Product

Resources

About